Helen van Aggelen

Helen van Aggelen is an accomplished data science and machine learning professional with extensive experience in drug discovery and genomics. Currently, as Associate Director at Septerna since May 2023, Helen leads the development of a DEL hit finding and ML platform on AWS for GPCR drug discovery. Previously, Helen served as Director of Data Science at Seranova Bio, where an end-to-end platform for autoantibody reactivity profile discovery was created. Helen also had a significant role at Zymergen as Staff Data Scientist, where a data-driven platform for drug discovery was developed. In earlier positions at Philips and Arc Bio, Helen contributed to infectious disease genomics and metagenomic diagnostics, respectively. Helen's academic background includes a PhD in Chemistry from Ghent University and postdoctoral research at renowned institutions such as MIT and Duke University.